Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Amgen

Eli Lilly

Altimmune

AstraZeneca

Structure Therapeutics Inc

Viking Therapeutics

Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.

Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

Bagsværd, Denmark, 06 May 2024 – This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 06 May 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 5,427,801,225.00 million from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S' 2024 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The transaction price is DKK 860.02 per share and has been calculated as the three-day volume weighted average market price from 2 May 2024 to 6 May 2024 in the open window following the announcement of Novo Nordisk A/S' quarterly financial results.

Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme

The Bill & Melinda Gates Foundation is committing $100 million to a new joint partnership that will support innovation and research that address global health challenges.

Gates Foundation joins Novo Nordisk, Wellcome on $300M global health effort

The Bill & Melinda Gates Foundation, Wellcome Trust and Novo Nordisk Foundation joined forces on Monday to tackle some of the world's most pressing health problems, an endeavor that pulls together three of philanthropy's biggest players to tap developments in science and technology at a time when funding and attention for global health among governments is faltering.

Gates, Novo Nordisk And Wellcome Commit $300 Million To Climate Change, Infectious Diseases And Nutrition

Pfizer

The outlook for Pfizer's experimental obesity drug danuglipron is murky at best. Pfizer could pick up another obesity drug via an acquisition, but management says a near-term deal is unlikely.

Can Pfizer Challenge Lilly and Novo Nordisk in the Obesity Market?

Broadcom

Tencent Holdings Limited

There are no true “under-the-radar stocks” in the traditional sense regarding companies with a market capitalization large enough to be viable candidates for a $1 trillion valuation in just six years. However, there are many overlooked gems whose immense potential fails to garner the attention it deserves from investors.

3 Under-The-Radar Stocks That Could Be Worth Over $1 Trillion by 2030

Amgen's update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and Eli Lilly lower.

Amgen stock soars on weight loss injection progress as Novo Nordisk, Eli Lilly shares slide

Novo Nordisk (NYSE:NVO)'s latest results have impressed analysts at Citi, who see little to stop the pharma's value increasing even further as weight control drug Wegovy grows in the US. “While periodic supply constraints continue to impact the business, scaling supply remains management's number one priority.

Novo Nordisk continues to impress, says buyer Citi

Analysts pored over the details in its first-quarter results and monitored a potential rival weight loss treatment.

Wegovy maker Novo Nordisk down 4%, heads for worst day since October

Catalent

The U.S. Federal Trade Commission has sought additional information about a $16.5 billion deal by Novo Nordisk's parent to buy manufacturing subcontractor Catalent.

US FTC seeks more information on Novo Nordisk parent-Catalent deal

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing its proprietary structural biology and computational chemistry platform, ReSOLVE™, to develop differentiated small molecule therapeutics, today announced that its partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001 (formerly known as VENT-01) – an oral NLRP3 inhibitor licensed by Novo Nordisk in September 2022. “.

Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk

An EU study confirms there's no evidence linking Ozempic and Wegovy to an increase in suicidal thoughts. Side effects could be a key differentiator when it comes to which weight-loss and diabetes drugs succeed.

This Is a Huge Sigh of Relief for Novo Nordisk Investors

Shares in Danish drugmaker Novo Nordisk dropped as much as 5.3% on Friday, set for their biggest one-day fall since August 2022, after rival Amgen said it was encouraged by interim trial data on its experimental obesity drug.

Novo Nordisk drops 5% after rival Amgen teases weight-loss drug data

Novo Nordisk said it will cut prices of Wegovy amid rising sales and competition. Sales of the blockbuster drug more than doubled in the first quarter year-on-year.

Blockbuster weight loss drug Wegovy's sales just doubled — and could heat up even more with a price cut

Danish drugmaker Novo Nordisk, the creator of Ozempic and Wegovy, announced a shocking statistic Thursday: Over 25,000 people begin Wegovy each week. The number is five times larger than the numbers from December—about 5,000 new users a week.

25,000 people begin taking Wegovy each week, but Novo Nordisk stock is sinking anyway

Novo Nordisk A/S (NVO) Q1 2024 Earnings Conference Call May 2, 2024 7:00 AM ET Company Participants Lars Fruergaard Jørgensen - Chief Executive Officer Camilla Sylvest - Executive Vice President, Head of Commercial Strategy & Corporate Affairs Doug Langa - Executive Vice President, Head of North America Operations Martin Holst Lange - Executive Vice President, Head of Development Karsten Munk Knudsen - Chief Financial Officer Daniel Bohsen - Head of Investor Relations Conference Call Participants Michael Nedelcovych - TD Cowen Richard Vosser - JPMorgan Louise Chen - Cantor Fitzgerald Evan Seigerman - BMO Capital Markets Sachin Jain - Bank of America Peter Verdult - Citi Simon Baker - Redburn Atlantic Florent Cespedes - Bernstein Mark Purcell - Morgan Stanley Harry Sephton - UBS Richard Parkes - BNP Paribas Exxon Michael Novod - Nordea Operator Good day! And thank you for standing by.

Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript

Novo Nordisk (NYSE:NVO), Europe's biggest company, said it is ramping up production of its diabtes/weightloss drugs Wegovy and Ozempic, after patient numbers quadrupled in the US. But the Danish colossus said it has cut the price of its blockbuster injected treatment due to competition from rivals like Eli Lilly.

Novo Nordisk ups guidance buts cuts Wegovy price

Novo Nordisk (NVO) reports better-than-expected first-quarter results, beating both earnings and revenues, driven by strong sales of Diabetes and Obesity care products.

Novo Nordisk (NVO) Q1 Earnings Beat, GLP-1 Drugs Boost Sales

Moderna

Here are two biotech stocks to watch after their recent earnings report.

2 Biotech Stocks To Watch Today Amid Earnings

Novo Nordisk (NVO) reported first-quarter earnings Thursday that beat analysts' estimates as demand surged for its weight loss drugs, Ozempic and Wegovy.

Novo Nordisk's Earnings Beat Estimates on Surging Demand for Its Weight-Loss Drugs

Novo Nordisk has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have increased, a senior executive said on Thursday.

Novo Nordisk: Wegovy, Ozempic prices in US fell in Q1

Novo Nordisk stock came under mild selling pressure early Thursday, after the company reported Q1 results and lifted guidance.

Novo Nordisk Dips As Q1 Wegovy Sales Double, But Miss Target

Novo Nordisk raised its full-year guidance to reflect better pricing in the U.S. and as global demand for its hit weight-loss and diabetes drugs continues to outstrip supply.

WegovySales More Than Double as Demand Soars

Novo Nordisk (NYSE:NVO), Europe's biggest company, said it is ramping up production of its diabtes/weightloss drugs Wegovy and Ozempic, after patient numbers quadrupled in the US. First-quarter sales came in at 65.35 billion Danish krone, beating forecasts of DKK 63.75 billion, including almost DKK 35 billion from the drug.

News for Novo Nordisk Stock (NVO)